Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-01-28

AUTHORS

Ann M. McNeill, Glenn Davies, Eliza Kruger, Stacey Kowal, Tim Reason, Flavia Ejzykowicz, Hakima Hannachi, Nilo Cater, Euan McLeod

ABSTRACT

IntroductionErtugliflozin is a new sodium-glucose co-transporter-2 inhibitor (SGLT2i) for the treatment of type 2 diabetes mellitus. As there are no head-to-head trials comparing the efficacy of SGLT2is, the primary objective of this analysis was to indirectly compare ertugliflozin to other SGLT2i in patient populations with inadequately controlled glycated hemoglobin (HbA1c > 7.0%) and previously treated with either diet/exercise, metformin alone or metformin plus a dipeptidyl peptidase-4 inhibitor (DPP4i).MethodsA systematic literature review (SLR) identified randomized controlled trials (RCTs) reporting outcomes at 24–26 weeks of treatment. Comparators to ertugliflozin were the SGLT2is canagliflozin, dapagliflozin and empagliflozin, with non-SGLT2i comparators also evaluated third-line [insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs)]. Outcomes were change from baseline in HbA1c, weight and systolic blood pressure (SBP) as well as HbA1c < 7% and key safety events. Bayesian network meta-analysis was used to synthesize evidence. Results are presented as the median of the mean difference (MD) or as odds ratios with 95% credible intervals (CrI).ResultsIn patients uncontrolled on diet/exercise, the efficacy of ertugliflozin 5 mg monotherapy was not significantly different from that of other low-dose SGLT2is in terms of HbA1c reduction, while ertugliflozin 15 mg was more effective than dapagliflozin 10 mg (MD − 0.36%, CrI − 0.65, − 0.08) and empagliflozin 25 mg (MD − 0.31%, CrI − 0.58, − 0.04). As add-on therapy to metformin, ertugliflozin 5 mg was more effective in lowering HbA1c than dapagliflozin 5 mg (MD − 0.22%, CrI − 0.42, − 0.02), and ertugliflozin 15 mg was more effective than dapagliflozin 10 mg (MD − 0.26%, CrI − 0.46, − 0.06) and empagliflozin 25 mg (MD − 0.23%, CrI − 0.44, − 0.03). Among patients uncontrolled on combination therapy metformin plus a DPP4i, no relevant RCTs with insulin were identified from the SLR. One study with a GLP-1 RA was included in a sensitivity analysis due to limited data. There were no differences between ertugliflozin 5 or 15 mg and other SGLT2is, with the exception of dapagliflozin 10 mg, which was significantly less effective when added to sitagliptin and metformin. Overall, there were no other significant differences for remaining efficacy and safety outcomes except for a lower SBP for canagliflozin 300 mg compared to ertugliflozin 15 mg in the diet/exercise population.ConclusionsIndirect comparisons for HbA1c reduction found that ertugliflozin 5 mg was more effective than dapagliflozin 5 mg when added to metformin monotherapy, whereas ertugliflozin 15 mg was more effective than dapagliflozin 10 mg and empagliflozin 25 mg when added to diet/exercise and to metformin monotherapy. The HbA1c reduction associated with ertugliflozin was no different than that associated with canagliflozin across all populations.FundingMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Pfizer Inc., New York, NY, USA. More... »

PAGES

473-491

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s13300-019-0566-x

DOI

http://dx.doi.org/10.1007/s13300-019-0566-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111682508

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30689140


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Merck & Co., Inc., Kenilworth, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Merck & Co., Inc., Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McNeill", 
        "givenName": "Ann M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck & Co., Inc., Kenilworth, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Merck & Co., Inc., Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davies", 
        "givenName": "Glenn", 
        "id": "sg:person.0710401212.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710401212.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IQVIA, Parsippany, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418848.9", 
          "name": [
            "IQVIA, Parsippany, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kruger", 
        "givenName": "Eliza", 
        "id": "sg:person.011122037536.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011122037536.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IQVIA, Parsippany, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418848.9", 
          "name": [
            "IQVIA, Parsippany, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kowal", 
        "givenName": "Stacey", 
        "id": "sg:person.01300202725.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300202725.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "IQVIA, Parsippany, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.418848.9", 
          "name": [
            "IQVIA, Parsippany, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reason", 
        "givenName": "Tim", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck & Co., Inc., Kenilworth, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Merck & Co., Inc., Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ejzykowicz", 
        "givenName": "Flavia", 
        "id": "sg:person.01077163317.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077163317.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Merck & Co., Inc., Kenilworth, NJ, USA", 
          "id": "http://www.grid.ac/institutes/grid.417993.1", 
          "name": [
            "Merck & Co., Inc., Kenilworth, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hannachi", 
        "givenName": "Hakima", 
        "id": "sg:person.01101301445.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101301445.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cater", 
        "givenName": "Nilo", 
        "id": "sg:person.01347267522.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347267522.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer, Tadworth, UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer, Tadworth, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McLeod", 
        "givenName": "Euan", 
        "id": "sg:person.01337061043.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337061043.47"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s40265-014-0337-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023128445", 
          "https://doi.org/10.1007/s40265-014-0337-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-013-3039-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016452155", 
          "https://doi.org/10.1007/s00125-013-3039-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1741-7015-12-93", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036633908", 
          "https://doi.org/10.1186/1741-7015-12-93"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1008929526011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031552564", 
          "https://doi.org/10.1023/a:1008929526011"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-018-0482-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106225069", 
          "https://doi.org/10.1007/s13300-018-0482-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-017-0354-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1100078266", 
          "https://doi.org/10.1007/s13300-017-0354-4"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-01-28", 
    "datePublishedReg": "2019-01-28", 
    "description": "IntroductionErtugliflozin is a new sodium-glucose co-transporter-2 inhibitor (SGLT2i) for the treatment of type 2 diabetes mellitus. As there are no head-to-head trials comparing the efficacy of SGLT2is, the primary objective of this analysis was to indirectly compare ertugliflozin to other SGLT2i in patient populations with inadequately controlled glycated hemoglobin (HbA1c\u2009>\u20097.0%) and previously treated with either diet/exercise, metformin alone or metformin plus a dipeptidyl peptidase-4 inhibitor (DPP4i).MethodsA systematic literature review (SLR) identified randomized controlled trials (RCTs) reporting outcomes at 24\u201326\u00a0weeks of treatment. Comparators to ertugliflozin were the SGLT2is canagliflozin, dapagliflozin and empagliflozin, with non-SGLT2i comparators also evaluated third-line [insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs)]. Outcomes were change from baseline in HbA1c, weight and systolic blood pressure (SBP) as well as HbA1c\u2009<\u20097% and key safety events. Bayesian network meta-analysis was used to synthesize evidence. Results are presented as the median of the mean difference (MD) or as odds ratios with 95% credible intervals (CrI).ResultsIn patients uncontrolled on diet/exercise, the efficacy of ertugliflozin 5\u00a0mg monotherapy was not significantly different from that of other low-dose SGLT2is in terms of HbA1c reduction, while ertugliflozin 15\u00a0mg was more effective than dapagliflozin 10\u00a0mg (MD \u2212\u20090.36%, CrI \u2212\u20090.65, \u2212\u20090.08) and empagliflozin 25\u00a0mg (MD \u2212\u20090.31%, CrI \u2212\u20090.58, \u2212\u20090.04). As add-on therapy to metformin, ertugliflozin 5\u00a0mg was more effective in lowering HbA1c than dapagliflozin 5\u00a0mg (MD \u2212\u20090.22%, CrI \u2212\u20090.42, \u2212\u20090.02), and ertugliflozin 15\u00a0mg was more effective than dapagliflozin 10\u00a0mg (MD \u2212\u20090.26%, CrI \u2212\u20090.46, \u2212\u20090.06) and empagliflozin 25\u00a0mg (MD \u2212\u20090.23%, CrI \u2212\u20090.44, \u2212\u20090.03). Among patients uncontrolled on combination therapy metformin plus a DPP4i, no relevant RCTs with insulin were identified from the SLR. One study with a GLP-1 RA was included in a sensitivity analysis due to limited data. There were no differences between ertugliflozin 5 or 15\u00a0mg and other SGLT2is, with the exception of dapagliflozin 10\u00a0mg, which was significantly less effective when added to sitagliptin and metformin. Overall, there were no other significant differences for remaining efficacy and safety outcomes except for a lower SBP for canagliflozin 300\u00a0mg compared to ertugliflozin 15\u00a0mg in the diet/exercise population.ConclusionsIndirect comparisons for HbA1c reduction found that ertugliflozin 5\u00a0mg was more effective than dapagliflozin 5\u00a0mg when added to metformin monotherapy, whereas ertugliflozin 15\u00a0mg was more effective than dapagliflozin 10\u00a0mg and empagliflozin 25\u00a0mg when added to diet/exercise and to metformin monotherapy. The HbA1c reduction associated with ertugliflozin was no different than that associated with canagliflozin across all populations.FundingMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Pfizer Inc., New York, NY, USA.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s13300-019-0566-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1044057", 
        "issn": [
          "1869-6953", 
          "1869-6961"
        ], 
        "name": "Diabetes Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "10"
      }
    ], 
    "keywords": [
      "sodium-glucose co-transporter-2 inhibitors", 
      "dipeptidyl peptidase-4 inhibitors", 
      "systolic blood pressure", 
      "diet/exercise", 
      "dapagliflozin 10", 
      "ertugliflozin 15", 
      "dapagliflozin 5", 
      "ertugliflozin 5", 
      "lower systolic blood pressure", 
      "type 2 diabetes mellitus", 
      "systematic literature review", 
      "mean difference", 
      "trials (RCTs) reporting outcomes", 
      "GLP-1 RAs", 
      "peptidase-4 inhibitors", 
      "weeks of treatment", 
      "Network Meta-Analysis", 
      "anti-hyperglycemic agents", 
      "subsidiary of Merck", 
      "canagliflozin 300", 
      "metformin monotherapy", 
      "HbA1c reduction", 
      "head trials", 
      "relevant RCTs", 
      "ResultsIn patients", 
      "diabetes mellitus", 
      "blood pressure", 
      "Dohme Corp.", 
      "patient population", 
      "glycated hemoglobin", 
      "odds ratio", 
      "safety outcomes", 
      "monotherapy", 
      "metformin", 
      "type 2", 
      "Meta-Analysis", 
      "literature review", 
      "ertugliflozin", 
      "reporting outcomes", 
      "safety events", 
      "Pfizer Inc.", 
      "limited data", 
      "exercise population", 
      "efficacy", 
      "significant differences", 
      "canagliflozin", 
      "patients", 
      "therapy", 
      "outcomes", 
      "exercise", 
      "treatment", 
      "primary objective", 
      "inhibitors", 
      "population", 
      "mellitus", 
      "empagliflozin", 
      "review", 
      "dapagliflozin", 
      "RCTs", 
      "sitagliptin", 
      "differences", 
      "insulin", 
      "baseline", 
      "trials", 
      "weeks", 
      "hemoglobin", 
      "median", 
      "reduction", 
      "comparator", 
      "credible intervals", 
      "Merck", 
      "add", 
      "agents", 
      "head", 
      "RA", 
      "evidence", 
      "intervals", 
      "weight", 
      "study", 
      "sensitivity analysis", 
      "New York", 
      "events", 
      "analysis", 
      "NY", 
      "pressure", 
      "changes", 
      "objective", 
      "exception", 
      "USA", 
      "Sharp", 
      "data", 
      "ratio", 
      "comparison", 
      "Kenilworth", 
      "Inc.", 
      "results", 
      "York", 
      "terms", 
      "NJ", 
      "Bayesian network", 
      "Corp.", 
      "Co.", 
      "network", 
      "subsidiaries", 
      "IntroductionErtugliflozin", 
      "new sodium-glucose co-transporter-2 inhibitor", 
      "co-transporter-2 inhibitor", 
      "efficacy of SGLT2is", 
      "non-SGLT2i comparators", 
      "key safety events", 
      "low-dose SGLT2is", 
      "combination therapy metformin", 
      "therapy metformin", 
      "diet/exercise population", 
      "ConclusionsIndirect comparisons", 
      "FundingMerck Sharp"
    ], 
    "name": "Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis", 
    "pagination": "473-491", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111682508"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s13300-019-0566-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30689140"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s13300-019-0566-x", 
      "https://app.dimensions.ai/details/publication/pub.1111682508"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:35", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_808.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s13300-019-0566-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0566-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0566-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0566-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s13300-019-0566-x'


 

This table displays all metadata directly associated to this object as RDF triples.

265 TRIPLES      22 PREDICATES      148 URIs      134 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s13300-019-0566-x schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N837fa60d91904fc19b33e19aae629066
4 schema:citation sg:pub.10.1007/s00125-013-3039-1
5 sg:pub.10.1007/s13300-017-0354-4
6 sg:pub.10.1007/s13300-018-0482-5
7 sg:pub.10.1007/s40265-014-0337-y
8 sg:pub.10.1023/a:1008929526011
9 sg:pub.10.1186/1741-7015-12-93
10 schema:datePublished 2019-01-28
11 schema:datePublishedReg 2019-01-28
12 schema:description IntroductionErtugliflozin is a new sodium-glucose co-transporter-2 inhibitor (SGLT2i) for the treatment of type 2 diabetes mellitus. As there are no head-to-head trials comparing the efficacy of SGLT2is, the primary objective of this analysis was to indirectly compare ertugliflozin to other SGLT2i in patient populations with inadequately controlled glycated hemoglobin (HbA1c > 7.0%) and previously treated with either diet/exercise, metformin alone or metformin plus a dipeptidyl peptidase-4 inhibitor (DPP4i).MethodsA systematic literature review (SLR) identified randomized controlled trials (RCTs) reporting outcomes at 24–26 weeks of treatment. Comparators to ertugliflozin were the SGLT2is canagliflozin, dapagliflozin and empagliflozin, with non-SGLT2i comparators also evaluated third-line [insulin and glucagon-like peptide-1 receptor agonists (GLP-1 RAs)]. Outcomes were change from baseline in HbA1c, weight and systolic blood pressure (SBP) as well as HbA1c < 7% and key safety events. Bayesian network meta-analysis was used to synthesize evidence. Results are presented as the median of the mean difference (MD) or as odds ratios with 95% credible intervals (CrI).ResultsIn patients uncontrolled on diet/exercise, the efficacy of ertugliflozin 5 mg monotherapy was not significantly different from that of other low-dose SGLT2is in terms of HbA1c reduction, while ertugliflozin 15 mg was more effective than dapagliflozin 10 mg (MD − 0.36%, CrI − 0.65, − 0.08) and empagliflozin 25 mg (MD − 0.31%, CrI − 0.58, − 0.04). As add-on therapy to metformin, ertugliflozin 5 mg was more effective in lowering HbA1c than dapagliflozin 5 mg (MD − 0.22%, CrI − 0.42, − 0.02), and ertugliflozin 15 mg was more effective than dapagliflozin 10 mg (MD − 0.26%, CrI − 0.46, − 0.06) and empagliflozin 25 mg (MD − 0.23%, CrI − 0.44, − 0.03). Among patients uncontrolled on combination therapy metformin plus a DPP4i, no relevant RCTs with insulin were identified from the SLR. One study with a GLP-1 RA was included in a sensitivity analysis due to limited data. There were no differences between ertugliflozin 5 or 15 mg and other SGLT2is, with the exception of dapagliflozin 10 mg, which was significantly less effective when added to sitagliptin and metformin. Overall, there were no other significant differences for remaining efficacy and safety outcomes except for a lower SBP for canagliflozin 300 mg compared to ertugliflozin 15 mg in the diet/exercise population.ConclusionsIndirect comparisons for HbA1c reduction found that ertugliflozin 5 mg was more effective than dapagliflozin 5 mg when added to metformin monotherapy, whereas ertugliflozin 15 mg was more effective than dapagliflozin 10 mg and empagliflozin 25 mg when added to diet/exercise and to metformin monotherapy. The HbA1c reduction associated with ertugliflozin was no different than that associated with canagliflozin across all populations.FundingMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, and Pfizer Inc., New York, NY, USA.
13 schema:genre article
14 schema:inLanguage en
15 schema:isAccessibleForFree true
16 schema:isPartOf N3e6295a882ed46d9a9852e2dce3714c5
17 Nf7c4883e247141b0a68c1648d536c3f1
18 sg:journal.1044057
19 schema:keywords Bayesian network
20 Co.
21 ConclusionsIndirect comparisons
22 Corp.
23 Dohme Corp.
24 FundingMerck Sharp
25 GLP-1 RAs
26 HbA1c reduction
27 Inc.
28 IntroductionErtugliflozin
29 Kenilworth
30 Merck
31 Meta-Analysis
32 NJ
33 NY
34 Network Meta-Analysis
35 New York
36 Pfizer Inc.
37 RA
38 RCTs
39 ResultsIn patients
40 Sharp
41 USA
42 York
43 add
44 agents
45 analysis
46 anti-hyperglycemic agents
47 baseline
48 blood pressure
49 canagliflozin
50 canagliflozin 300
51 changes
52 co-transporter-2 inhibitor
53 combination therapy metformin
54 comparator
55 comparison
56 credible intervals
57 dapagliflozin
58 dapagliflozin 10
59 dapagliflozin 5
60 data
61 diabetes mellitus
62 diet/exercise
63 diet/exercise population
64 differences
65 dipeptidyl peptidase-4 inhibitors
66 efficacy
67 efficacy of SGLT2is
68 empagliflozin
69 ertugliflozin
70 ertugliflozin 15
71 ertugliflozin 5
72 events
73 evidence
74 exception
75 exercise
76 exercise population
77 glycated hemoglobin
78 head
79 head trials
80 hemoglobin
81 inhibitors
82 insulin
83 intervals
84 key safety events
85 limited data
86 literature review
87 low-dose SGLT2is
88 lower systolic blood pressure
89 mean difference
90 median
91 mellitus
92 metformin
93 metformin monotherapy
94 monotherapy
95 network
96 new sodium-glucose co-transporter-2 inhibitor
97 non-SGLT2i comparators
98 objective
99 odds ratio
100 outcomes
101 patient population
102 patients
103 peptidase-4 inhibitors
104 population
105 pressure
106 primary objective
107 ratio
108 reduction
109 relevant RCTs
110 reporting outcomes
111 results
112 review
113 safety events
114 safety outcomes
115 sensitivity analysis
116 significant differences
117 sitagliptin
118 sodium-glucose co-transporter-2 inhibitors
119 study
120 subsidiaries
121 subsidiary of Merck
122 systematic literature review
123 systolic blood pressure
124 terms
125 therapy
126 therapy metformin
127 treatment
128 trials
129 trials (RCTs) reporting outcomes
130 type 2
131 type 2 diabetes mellitus
132 weeks
133 weeks of treatment
134 weight
135 schema:name Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis
136 schema:pagination 473-491
137 schema:productId N06459b1f10464862afe094702d65ae86
138 N1fdb91d1f7f84ce8940a2044b49fe17c
139 Nf3521ab7ebf349cb9306d2b18d5d80ed
140 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111682508
141 https://doi.org/10.1007/s13300-019-0566-x
142 schema:sdDatePublished 2021-11-01T18:35
143 schema:sdLicense https://scigraph.springernature.com/explorer/license/
144 schema:sdPublisher N1ea044aed8cb4c7ca2841760977faead
145 schema:url https://doi.org/10.1007/s13300-019-0566-x
146 sgo:license sg:explorer/license/
147 sgo:sdDataset articles
148 rdf:type schema:ScholarlyArticle
149 N06459b1f10464862afe094702d65ae86 schema:name pubmed_id
150 schema:value 30689140
151 rdf:type schema:PropertyValue
152 N1d179f4d6c5047d191f868be3299b36d rdf:first N5aba9d1ec219440590d2fdedccc384be
153 rdf:rest N5bb9355f11174190ac4b1e2812ad115f
154 N1ea044aed8cb4c7ca2841760977faead schema:name Springer Nature - SN SciGraph project
155 rdf:type schema:Organization
156 N1fdb91d1f7f84ce8940a2044b49fe17c schema:name doi
157 schema:value 10.1007/s13300-019-0566-x
158 rdf:type schema:PropertyValue
159 N3e6295a882ed46d9a9852e2dce3714c5 schema:volumeNumber 10
160 rdf:type schema:PublicationVolume
161 N4624b6851a444cbe9eb6a497eaca6505 rdf:first sg:person.01337061043.47
162 rdf:rest rdf:nil
163 N5aba9d1ec219440590d2fdedccc384be schema:affiliation grid-institutes:grid.418848.9
164 schema:familyName Reason
165 schema:givenName Tim
166 rdf:type schema:Person
167 N5bb9355f11174190ac4b1e2812ad115f rdf:first sg:person.01077163317.63
168 rdf:rest Nd15846ff95834e6fab213be2d8650b53
169 N633225a0a8d844c38853dfd28e4341af rdf:first sg:person.0710401212.06
170 rdf:rest N75648dfd45a948578782095246bc8d2b
171 N75648dfd45a948578782095246bc8d2b rdf:first sg:person.011122037536.96
172 rdf:rest Nbc6d98de12114e2dab8fd3b428cb4d99
173 N837fa60d91904fc19b33e19aae629066 rdf:first Nac3c6faa20614e9fa7931d86b8ef35a1
174 rdf:rest N633225a0a8d844c38853dfd28e4341af
175 Nac3c6faa20614e9fa7931d86b8ef35a1 schema:affiliation grid-institutes:grid.417993.1
176 schema:familyName McNeill
177 schema:givenName Ann M.
178 rdf:type schema:Person
179 Nbc6d98de12114e2dab8fd3b428cb4d99 rdf:first sg:person.01300202725.74
180 rdf:rest N1d179f4d6c5047d191f868be3299b36d
181 Ncefbac1ccd4f4b07866236022f9fd70a rdf:first sg:person.01347267522.97
182 rdf:rest N4624b6851a444cbe9eb6a497eaca6505
183 Nd15846ff95834e6fab213be2d8650b53 rdf:first sg:person.01101301445.58
184 rdf:rest Ncefbac1ccd4f4b07866236022f9fd70a
185 Nf3521ab7ebf349cb9306d2b18d5d80ed schema:name dimensions_id
186 schema:value pub.1111682508
187 rdf:type schema:PropertyValue
188 Nf7c4883e247141b0a68c1648d536c3f1 schema:issueNumber 2
189 rdf:type schema:PublicationIssue
190 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
191 schema:name Medical and Health Sciences
192 rdf:type schema:DefinedTerm
193 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
194 schema:name Clinical Sciences
195 rdf:type schema:DefinedTerm
196 sg:journal.1044057 schema:issn 1869-6953
197 1869-6961
198 schema:name Diabetes Therapy
199 schema:publisher Springer Nature
200 rdf:type schema:Periodical
201 sg:person.01077163317.63 schema:affiliation grid-institutes:grid.417993.1
202 schema:familyName Ejzykowicz
203 schema:givenName Flavia
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01077163317.63
205 rdf:type schema:Person
206 sg:person.01101301445.58 schema:affiliation grid-institutes:grid.417993.1
207 schema:familyName Hannachi
208 schema:givenName Hakima
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01101301445.58
210 rdf:type schema:Person
211 sg:person.011122037536.96 schema:affiliation grid-institutes:grid.418848.9
212 schema:familyName Kruger
213 schema:givenName Eliza
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011122037536.96
215 rdf:type schema:Person
216 sg:person.01300202725.74 schema:affiliation grid-institutes:grid.418848.9
217 schema:familyName Kowal
218 schema:givenName Stacey
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300202725.74
220 rdf:type schema:Person
221 sg:person.01337061043.47 schema:affiliation grid-institutes:grid.418566.8
222 schema:familyName McLeod
223 schema:givenName Euan
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01337061043.47
225 rdf:type schema:Person
226 sg:person.01347267522.97 schema:affiliation grid-institutes:grid.410513.2
227 schema:familyName Cater
228 schema:givenName Nilo
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01347267522.97
230 rdf:type schema:Person
231 sg:person.0710401212.06 schema:affiliation grid-institutes:grid.417993.1
232 schema:familyName Davies
233 schema:givenName Glenn
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710401212.06
235 rdf:type schema:Person
236 sg:pub.10.1007/s00125-013-3039-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016452155
237 https://doi.org/10.1007/s00125-013-3039-1
238 rdf:type schema:CreativeWork
239 sg:pub.10.1007/s13300-017-0354-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100078266
240 https://doi.org/10.1007/s13300-017-0354-4
241 rdf:type schema:CreativeWork
242 sg:pub.10.1007/s13300-018-0482-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106225069
243 https://doi.org/10.1007/s13300-018-0482-5
244 rdf:type schema:CreativeWork
245 sg:pub.10.1007/s40265-014-0337-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1023128445
246 https://doi.org/10.1007/s40265-014-0337-y
247 rdf:type schema:CreativeWork
248 sg:pub.10.1023/a:1008929526011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031552564
249 https://doi.org/10.1023/a:1008929526011
250 rdf:type schema:CreativeWork
251 sg:pub.10.1186/1741-7015-12-93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036633908
252 https://doi.org/10.1186/1741-7015-12-93
253 rdf:type schema:CreativeWork
254 grid-institutes:grid.410513.2 schema:alternateName Pfizer, New York, NY, USA
255 schema:name Pfizer, New York, NY, USA
256 rdf:type schema:Organization
257 grid-institutes:grid.417993.1 schema:alternateName Merck & Co., Inc., Kenilworth, NJ, USA
258 schema:name Merck & Co., Inc., Kenilworth, NJ, USA
259 rdf:type schema:Organization
260 grid-institutes:grid.418566.8 schema:alternateName Pfizer, Tadworth, UK
261 schema:name Pfizer, Tadworth, UK
262 rdf:type schema:Organization
263 grid-institutes:grid.418848.9 schema:alternateName IQVIA, Parsippany, NJ, USA
264 schema:name IQVIA, Parsippany, NJ, USA
265 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...